Physician profile
Robert Nickelson
NPI 1023019064
$3,721.20
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,766 · 2020: $807 · 2021: $110 · 2023: $37.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,254.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $349.67 | 2019-2021 | |
| Janssen Biotech, INC. | $224.85 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $173.06 | 2019-2020 | |
| Pfizer INC. | $152.48 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.93 | 2019 | |
| Amgen INC. | $143.12 | 2019 | |
| Bard Peripheral Vascular, INC. | $125.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $110.34 | 2019-2020 | |
| Lilly USA, LLC | $110.30 | 2019-2021 | |
| Eisai INC. | $108.75 | 2019 | |
| Daiichi Sankyo INC. | $105.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.12 | 2019 | |
| Genentech USA, INC. | $69.49 | 2019-2020 | |
| Gilead Sciences, INC. | $66.66 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $57.45 | 2019-2020 | |
| Celgene Corporation | $47.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $37.74 | 2023 | Imbruvica, Epkinly |
| Janssen Pharmaceuticals, INC | $32.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.12 | 2019 | |
| Incyte Corporation | $29.73 | 2019-2020 | |
| Astellas Pharma US INC | $25.21 | 2019 | |
| Puma Biotechnology, INC. | $25.08 | 2019 | |
| Verastem, INC. | $23.71 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $22.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.69 | 2019 | |
| Tesaro, INC. | $20.06 | 2019 | |
| Taiho Oncology, INC. | $18.67 | 2019 | |
| Glaxosmithkline, LLC. | $15.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 | |
| Exelixis INC. | $15.13 | 2019 | |
| Advanced Accelerator Applications | $14.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.64 | 2020 | |
| Emd Serono, INC. | $12.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nickelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.